[Daily and intermittent regimens using ethambutol and rifampicin in the treatment of unresponsive cases. (Evaluation after 1 year.) II. Side effects].
D002986:Clinical Trials as Topic; D004342:Drug Hypersensitivity / Q000209:etiology; D004359:Drug Therapy, Combination; D004977:Ethambutol / Q000009:adverse effects* / Q000627:therapeutic use; D005334:Fever / Q000139:chemically induced; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006801:Humans; D007565:Jaundice / Q000139:chemically induced; D011696:Purpura, Thrombocytopenic / Q000139:chemically induced; D012131:Respiratory Insufficiency / Q000139:chemically induced; D012293:Rifampin / Q000009:adverse effects* / Q000627:therapeutic use; D012877:Skin Manifestations; D013997:Time Factors; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy*
D004977:Ethambutol; D012293:Rifampin
Regimes quotidiens et regimes intermittents d'ethambutol et rifampicine dans le traitement des cas d'echec (2) (Bilan a 1 an). II. Reactions secondaires